MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 10-09-2025
Neogen Corporation Operating Income 2011-2025 | NEOG
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Neogen Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.06 B | 58.7 M | 37.5 M | 58.6 M | 74.2 M | 67.5 M | 68.1 M | 70.2 M | 64.9 M | 56.4 M | 53.1 M | 43.4 M | 40.7 M | 33.7 M | 35.8 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 74.2 M | -1.06 B | -19.9 M |
Quarterly Operating Income Neogen Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -16.1 M | - | 5.42 M | -457 M | 2.26 M | - | 12 M | 14.5 M | 19.1 M | - | 15.7 M | -7.66 M | 6.06 M | -1.59 M | 6.38 M | 12.5 M | 21.7 M | 34.2 M | 15.8 M | 19.2 M | 18.9 M | 19.2 M | 13 M | 18.3 M | 16.3 M | 18.3 M | 16.3 M | 18.2 M | 16.5 M | 18.2 M | 16.5 M | 18 M | 16.4 M | 18 M | 16.4 M | 16.9 M | 14.7 M | 16.9 M | 14.7 M | 14.6 M | 14.9 M | 14.6 M | 12.2 M | 12.9 M | 13.4 M | 12.9 M | 13.4 M | 9.69 M | 12.4 M | 9.69 M | 12.4 M | 10.5 M | 10.3 M | 10.5 M | 10.3 M | 8.14 M | 9.35 M | 8.14 M | 9.35 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 34.2 M | -457 M | 4.53 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Brainsway Ltd.
BWAY
|
-5 M | $ 16.71 | -0.83 % | $ 99.4 M |  Israel |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 16.22 | 2.97 % | $ 175 M |  China |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
-104 M | $ 1.57 | -3.4 % | $ 2 M | USA |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 38.53 | -0.26 % | $ 1.07 B | USA |
 |
DarioHealth Corp.
DRIO
|
-56.2 M | $ 11.99 | 0.84 % | $ 340 M | Israel |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
DexCom
DXCM
|
598 M | $ 66.15 | -1.22 % | $ 25.5 B | USA |
 |
Danaher Corporation
DHR
|
4.86 B | $ 226.11 | -0.17 % | $ 165 B | USA |
 |
Exact Sciences Corporation
EXAS
|
-876 M | $ 101.52 | 0.01 % | $ 18.8 B | USA |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 26.92 | -0.81 % | $ 814 M | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M | China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
-203 M | $ 19.95 | -2.97 % | $ 1.07 B | USA |
 |
Celcuity
CELC
|
-113 M | $ 101.73 | -3.34 % | $ 4.01 B | USA |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Anixa Biosciences
ANIX
|
-13.8 M | $ 3.29 | -8.24 % | $ 105 K | USA |
 |
Co-Diagnostics
CODX
|
-42.7 M | $ 0.31 | -9.7 % | $ 9.1 M | USA |
 |
IQVIA Holdings
IQV
|
2.2 B | $ 221.67 | -0.25 % | $ 40.2 B | USA |
 |
Guardant Health
GH
|
-444 M | $ 103.94 | 1.83 % | $ 12.8 B | USA |
 |
Aspira Women's Health
AWH
|
-32.8 M | - | -6.19 % | $ 10.5 M | USA |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
-833 M | $ 133.75 | -0.83 % | $ 21.3 B | USA |
 |
Charles River Laboratories International
CRL
|
227 M | $ 196.94 | 2.05 % | $ 10.1 B | USA |
 |
Quotient Limited
QTNT
|
-82.7 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
Quest Diagnostics Incorporated
DGX
|
1.35 B | $ 183.42 | 0.5 % | $ 20.4 B | USA |
|
Biodesix
BDSX
|
-34.5 M | $ 7.63 | -2.8 % | $ 989 M | USA |
 |
Myriad Genetics
MYGN
|
-124 M | $ 6.96 | -3.47 % | $ 631 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
1.09 B | $ 261.21 | -1.12 % | $ 21.9 B | USA |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 181.89 | -2.51 % | $ 15 B |  Irlanda |
 |
NeoGenomics
NEO
|
-92.1 M | $ 11.99 | 1.14 % | $ 1.52 B | USA |
 |
IDEXX Laboratories
IDXX
|
1.13 B | $ 698.37 | -0.83 % | $ 57.6 B | USA |
 |
Lantheus Holdings
LNTH
|
457 M | $ 67.15 | 0.79 % | $ 4.65 B | USA |
 |
Agilent Technologies
A
|
1.35 B | $ 139.73 | 0.05 % | $ 42.5 B | USA |
 |
Biomerica
BMRA
|
-5.14 M | $ 2.43 | -4.8 % | $ 5.58 M | USA |
 |
Bioventus
BVS
|
-81.7 M | $ 7.53 | -0.26 % | $ 472 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M | Israel |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |
 |
Pacific Biosciences of California
PACB
|
-334 M | $ 2.1 | -1.18 % | $ 533 M | USA |